MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Syndax Pharmaceuticals Inc

Deschisă

SectorSănătate

13.28 1.76

Rezumat

Modificarea prețului

24h

Curent

Minim

12.9

Maxim

13.3

Indicatori cheie

By Trading Economics

Venit

-10M

-94M

Vânzări

-4.8M

7.7M

EPS

-1.1

Marjă de profit

-1,226.159

Angajați

270

EBITDA

-5.3M

-89M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+163.08% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-295M

1B

Deschiderea anterioară

11.52

Închiderea anterioară

13.28

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Syndax Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 iul. 2024, 12:35 UTC

Principalele dinamici ale pieței

Syndax Pharma Shares Fall Premarket After FDA Extends Revumenib Review

Comparație

Modificare preț

Syndax Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

163.08% sus

Prognoză pe 12 luni

Medie 34.2 USD  163.08%

Maxim 51 USD

Minim 16 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSyndax Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

11

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

10.83 / N/ASuport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.